| Name | Title | Contact Details |
|---|---|---|
Mariko Motohashi |
Associate General Counsel | Profile |
Caryn McDowell |
Chief Legal and Administrative Officer and Corporate Secretary | Profile |
Prologin Technologies Inc is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Oncology Plus is a Brandon, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic`s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient`s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic`s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices.
DiNovo is a distributor of USP <797> <71> <800> compliance products, packaging solutions, and infusion supplies. We are designed to bring innovative products at a low cost to the healthcare market place.
Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.